信立泰(002294.SZ)：SAL0145药品临床试验申请获受理

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial application of its innovative drug SAL0145 injection, which is intended for the treatment of MASH [1] Group 1 - The clinical trial application for SAL0145 has been accepted, indicating progress in the drug development process [1] - SAL0145 is a siRNA drug developed by the company, showcasing its capability in innovative drug research and development [1] - The drug has independent intellectual property rights, highlighting the company's commitment to proprietary research [1]